| Inclusion Criteria: | 1) Histologically confirmed, relapsed or refractory mantle cell lymphoma requiring treatment.
2) No anti-cancer therapy for three weeks (6 weeks if rituximab, notrosurea, or Mitomycin C) prior to study initiation, and fully recovered from all toxicities associated with prior surgery, radiation treatments, chemotherapy, or immunotherapy.
3) An IRB-approved signed informed consent.
4) Age greater or equal to 18 years.
5) Expected survival greater than or equal to 3 months.
6) Pre-study performance status of 0, 1, or 2 according to the WHO criteria.
7) Acceptable hematologic status within two weeks prior to patient registration, including: Absolute neutrophil count (segmented neutrophils = bands x total WBC)greater than or equal to 1,500/mm^3; Platelets greater than or equal to 1000,000/mm^3.
8) Female patients who are not pregnant or lactating.
9) Men and women of reproductive potential who are following accepted birth control methods (as determined by the treating physician, however abstinence is not an acceptable method).
10) Patients previously on investigational Phase II anti-cancer drugs if no long-term toxicity is expected, and the patient has been off the drug for eight or more weeks with no significant post treatment toxicities observed.
11) Patients determined to have less than 25% bone marrow involvement with mantle cell lymphoma within six weeks of registration. Measurement to be determined by bilateral bone marrow biopsies. This criteria must be strictly met for adequate patient safety. |